Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells

Shotaro Ando, Jun Ichi Kawada, Takahiro Watanabe, Michio Suzuki, Yoshitaka Sato, Yuka Torii, Masato Asai, Fumi Goshima, Takayuki Murata, Norio Shimizu, Yoshinori Ito, Hiroshi Kimura

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV) infects not only B cells, but also T cells and natural killer (NK) cells, and is associated with T or NK cell lymphoma. These lymphoid malignancies are refractory to conventional chemotherapy. We examined the activation of the JAK3/STAT5 pathway in EBV-positive and -negative B, T and NK cell lines and in cell samples from patients with EBV-associated T cell lymphoma. We then evaluated the antitumor effects of the selective JAK3 inhibitor, tofacitinib, against these cell lines in vitro and in a murine xenograft model. We found that all EBV-positive T and NK cell lines and patient samples tested displayed activation of the JAK3/STAT5 pathway. Treatment of these cell lines with tofacitinib reduced the levels of phospho-STAT5, suppressed proliferation, induced G1 cell-cycle arrest and decreased EBV LMP1 and EBNA1 expression. An EBV-negative NK cell line was also sensitive to tofacitinib, whereas an EBV-infected NK cell line was more sensitive to tofacitinib than its parental line. Tofacitinib significantly inhibited the growth of established tumors in NOG mice. These findings suggest that tofacitinib may represent a useful therapeutic agent for patients with EBV-associated T and NK cell lymphoma.

Original languageEnglish
Pages (from-to)76793-76805
Number of pages13
JournalOncotarget
Volume7
Issue number47
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

G1 Phase Cell Cycle Checkpoints
Natural Killer T-Cells
Human Herpesvirus 4
Lymphoma
Growth
Cell Line
Neoplasms
Natural Killer Cells
tofacitinib
T-Cell Lymphoma
Proxy
Heterografts
B-Lymphocytes
T-Lymphocytes
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Ando, Shotaro ; Kawada, Jun Ichi ; Watanabe, Takahiro ; Suzuki, Michio ; Sato, Yoshitaka ; Torii, Yuka ; Asai, Masato ; Goshima, Fumi ; Murata, Takayuki ; Shimizu, Norio ; Ito, Yoshinori ; Kimura, Hiroshi. / Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. In: Oncotarget. 2016 ; Vol. 7, No. 47. pp. 76793-76805.
@article{48bbc39d8bda470db6d46bfc4b459542,
title = "Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells",
abstract = "Epstein-Barr virus (EBV) infects not only B cells, but also T cells and natural killer (NK) cells, and is associated with T or NK cell lymphoma. These lymphoid malignancies are refractory to conventional chemotherapy. We examined the activation of the JAK3/STAT5 pathway in EBV-positive and -negative B, T and NK cell lines and in cell samples from patients with EBV-associated T cell lymphoma. We then evaluated the antitumor effects of the selective JAK3 inhibitor, tofacitinib, against these cell lines in vitro and in a murine xenograft model. We found that all EBV-positive T and NK cell lines and patient samples tested displayed activation of the JAK3/STAT5 pathway. Treatment of these cell lines with tofacitinib reduced the levels of phospho-STAT5, suppressed proliferation, induced G1 cell-cycle arrest and decreased EBV LMP1 and EBNA1 expression. An EBV-negative NK cell line was also sensitive to tofacitinib, whereas an EBV-infected NK cell line was more sensitive to tofacitinib than its parental line. Tofacitinib significantly inhibited the growth of established tumors in NOG mice. These findings suggest that tofacitinib may represent a useful therapeutic agent for patients with EBV-associated T and NK cell lymphoma.",
author = "Shotaro Ando and Kawada, {Jun Ichi} and Takahiro Watanabe and Michio Suzuki and Yoshitaka Sato and Yuka Torii and Masato Asai and Fumi Goshima and Takayuki Murata and Norio Shimizu and Yoshinori Ito and Hiroshi Kimura",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.12529",
language = "English",
volume = "7",
pages = "76793--76805",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "47",

}

Ando, S, Kawada, JI, Watanabe, T, Suzuki, M, Sato, Y, Torii, Y, Asai, M, Goshima, F, Murata, T, Shimizu, N, Ito, Y & Kimura, H 2016, 'Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells', Oncotarget, vol. 7, no. 47, pp. 76793-76805. https://doi.org/10.18632/oncotarget.12529

Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. / Ando, Shotaro; Kawada, Jun Ichi; Watanabe, Takahiro; Suzuki, Michio; Sato, Yoshitaka; Torii, Yuka; Asai, Masato; Goshima, Fumi; Murata, Takayuki; Shimizu, Norio; Ito, Yoshinori; Kimura, Hiroshi.

In: Oncotarget, Vol. 7, No. 47, 01.01.2016, p. 76793-76805.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells

AU - Ando, Shotaro

AU - Kawada, Jun Ichi

AU - Watanabe, Takahiro

AU - Suzuki, Michio

AU - Sato, Yoshitaka

AU - Torii, Yuka

AU - Asai, Masato

AU - Goshima, Fumi

AU - Murata, Takayuki

AU - Shimizu, Norio

AU - Ito, Yoshinori

AU - Kimura, Hiroshi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Epstein-Barr virus (EBV) infects not only B cells, but also T cells and natural killer (NK) cells, and is associated with T or NK cell lymphoma. These lymphoid malignancies are refractory to conventional chemotherapy. We examined the activation of the JAK3/STAT5 pathway in EBV-positive and -negative B, T and NK cell lines and in cell samples from patients with EBV-associated T cell lymphoma. We then evaluated the antitumor effects of the selective JAK3 inhibitor, tofacitinib, against these cell lines in vitro and in a murine xenograft model. We found that all EBV-positive T and NK cell lines and patient samples tested displayed activation of the JAK3/STAT5 pathway. Treatment of these cell lines with tofacitinib reduced the levels of phospho-STAT5, suppressed proliferation, induced G1 cell-cycle arrest and decreased EBV LMP1 and EBNA1 expression. An EBV-negative NK cell line was also sensitive to tofacitinib, whereas an EBV-infected NK cell line was more sensitive to tofacitinib than its parental line. Tofacitinib significantly inhibited the growth of established tumors in NOG mice. These findings suggest that tofacitinib may represent a useful therapeutic agent for patients with EBV-associated T and NK cell lymphoma.

AB - Epstein-Barr virus (EBV) infects not only B cells, but also T cells and natural killer (NK) cells, and is associated with T or NK cell lymphoma. These lymphoid malignancies are refractory to conventional chemotherapy. We examined the activation of the JAK3/STAT5 pathway in EBV-positive and -negative B, T and NK cell lines and in cell samples from patients with EBV-associated T cell lymphoma. We then evaluated the antitumor effects of the selective JAK3 inhibitor, tofacitinib, against these cell lines in vitro and in a murine xenograft model. We found that all EBV-positive T and NK cell lines and patient samples tested displayed activation of the JAK3/STAT5 pathway. Treatment of these cell lines with tofacitinib reduced the levels of phospho-STAT5, suppressed proliferation, induced G1 cell-cycle arrest and decreased EBV LMP1 and EBNA1 expression. An EBV-negative NK cell line was also sensitive to tofacitinib, whereas an EBV-infected NK cell line was more sensitive to tofacitinib than its parental line. Tofacitinib significantly inhibited the growth of established tumors in NOG mice. These findings suggest that tofacitinib may represent a useful therapeutic agent for patients with EBV-associated T and NK cell lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84998636449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998636449&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12529

DO - 10.18632/oncotarget.12529

M3 - Article

C2 - 27732937

AN - SCOPUS:84998636449

VL - 7

SP - 76793

EP - 76805

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 47

ER -